Q4 2025 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2026-02-17 · accession 0001193125-26-053268
$286.5M
Reported value
11
Positions
2025-12-31
Period end
The Brief · Omega Fund Management, LLC · Q4 2025
AI · grounded in 13F
Omega Fund Management, LLC closed its position in enGene Holdings Inc., reducing its holding by $63,438. The fund also trimmed its stake in BBNX by 31.45%. Additional reductions occurred in KMTS, which saw a 16.54% decrease in shares, and NUVB, which was trimmed by 8.49%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67080N101 | NUVB | Nuvation Bio | $72.4M | 25.3% | 8,081,089 | Common | SOLE |
| 107924102 | BBOT | BridgeBio Oncology Therapeutics Inc. | $41.2M | 14.4% | 3,289,661 | Common | SOLE |
| 08659B102 | BBNX | Beta Bionics Inc. | $40.1M | 14.0% | 1,316,183 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc. | $37.1M | 12.9% | 2,204,650 | Common | SOLE |
| G52441105 | KMTS | Kestra Med Technologies Ltd | $36.4M | 12.7% | 1,373,591 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc. | $36.0M | 12.6% | 1,326,293 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $7.9M | 2.76% | 876,357 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $6.4M | 2.23% | 653,223 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $3.4M | 1.20% | 843,750 | Common | SOLE |
| 45175G207 | IMA | ImageneBio, Inc. | $3.1M | 1.10% | 455,361 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $2.4M | 0.84% | 248,672 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.